The therapeutic value of NF-κB inhibition was also investigated in relapsed pediatric T-ALL patients, where treatment with bortezomib in combination with multiagent chemotherapy was shown to be more effective than single treatments [183]. The gene discussed is NFKB1; the disease is acute lymphoblastic leukemia.